MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
41.53
+0.75
+1.84%
Opening 10:37 12/15 EST
OPEN
41.41
PREV CLOSE
40.78
HIGH
42.00
LOW
41.09
VOLUME
66.02K
TURNOVER
--
52 WEEK HIGH
52.24
52 WEEK LOW
14.63
MARKET CAP
753.83M
P/E (TTM)
6.73
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RIGL last week (1208-1212)?
Weekly Report · 7h ago
Insiders Who Sold Rigel Pharmaceuticals Made The Right Call As Market Cap Slides By US$97m
Simply Wall St · 3d ago
Rigel Pharmaceuticals Reports Promising Phase 1b Study Results
TipRanks · 4d ago
Rigel Pharmaceuticals Reports Updated Phase 1b Data for R289 in Lower-Risk MDS Patients
Reuters · 4d ago
Cantor Fitzgerald Keeps Their Hold Rating on Rigel (RIGL)
TipRanks · 12/08 13:16
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Terns Pharmaceuticals (TERN) and Pyxis Oncology (PYXS)
TipRanks · 12/08 11:40
Rigel’s Promising Pipeline and Strategic Advancements Justify Buy Rating
TipRanks · 12/08 11:15
Weekly Report: what happened at RIGL last week (1201-1205)?
Weekly Report · 12/08 10:30
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.